March 2010 - Launching of Mitosafe® at ToxEXPO.• The Mitosafe® platform is focused on a mechanistic analysis of mitochondrial functions
• The Mitostream® platform is a high content and phenotypic analysis of mitochondrial behavior. It aims at a better anticipation of the clinical tolerance of drugs early in the drug development process....ICDD's news release -
About ICDD
Founded in 2007, ICDD-sas is a science-based company, established as a contract research provider and with its activities focused on predictive toxicology. ICDD-sas uses its proprietary secondary screening platforms to select the safest drugs from the most active lead molecules developed and provided by our clients.
ICDD-sas is located close to Aix-en-Provence, France, in a state of the art Euro 2 million facility, covering 1600 square metres that acts as an incubator for emerging companies developing and commercializing innovative technologies.
The scientists at ICDD-sas boast a combined experience of 40 years in drug development, biochemistry, cell biology, neuroscience and immunology, having analyzed more than 100 new chemical entities at different stages of pre-clinical & clinical development.
The Drug Development Need
Drug development costs have increased 4-fold in the last 20 years, while the new treatments reaching the market each year have declined by almost 50%. Drug failure is usually due either to unexpected human toxicity or otherwise because of a lack of efficacy. Toxicity and lack of efficacy are often discovered only late in the costly clinical development program. ICDD-sas, using its proprietary know how, effectively addresses both of these challenges thereby enhancing the development of safer, more effective medicines, whilst reducing late stage development failures, development time and costs... About ICDD -
